atcd with significant morbidity and mortality [1] . Once acquired, the organism is seldom eradicated from the lungs of CF patients [2] , suggesting that this environment favours the survival and persistence of the organism. Strains of P. aemginosa isolated froa= the sputum of CF patients often exhibit in vitro a wide range of altered phenotypic properties which are not characteristic of isolates from the environment and other clinical sources. These include the production of alginate polysaccharidc [3] , loss of lipopolysaccharide (LPS) constituents, increased sensitivity to serum complement [4] and hypersensitivity to beta-lactam antibiotics [5] .
A feature of most pseudomonas species, including P. aemginosa, is their ability to utilise a wide variety of compounds as single carbon sources for growth [6] thus permitting survival in diverse nutrient-limited conditions. In 1975 Govan [7] observed that the conversion of isolates of P. aeruginosa from the mucoid to non-mucoid state was restrained by culture in minimal broth. lndecd, Speert et al. [8] proposed that in the CF lung, P. aen~ginosa probably grows in nutrientlimited conditions and they showed that phenotypic conversion of strains to mucoid production and LPS a|terations could occur when isolates were grown in vitro in a single carbon source. We 244 speculated that one way in which P. aemginosa persists in the CF lung might be by adaptation to the CF mucosal environment; mutants of P. aemginosa with specific requirements for nutrients which are present in relative excess may be selected. We therefore examined the growth requirements of isolates of P. aeruginosa from patients with CF and non-CF bronchiectasis and compared these with isolates from other clinical sources,
METHODS

Bacterial cultures
A collection of 513 isolates of P. aemghzosa which had all been stored on agar slopes at room temperature for up to 2 years were examined for auxotrophy. Four hundred and three were from the sputum of 136 CF patients from six different CF centrc~, i l from 11 non-CF bronchiec:atic patients f, ,~n ~, :he Royal Brompton Hospital, London, and 91 were from other clinical non-CF sources taken from 73 patients as follows: urinary tract (27, 15 from 14 patients with in-dwelling catheters); respiratory tract (16); skin (11); wound sites (7); stool (7); bone (7); blood (5); burns (4); drains (4); central lines (3) . Strains from eight environmental sites, such as sinks and bed-liners, isolated from four wards (non-CF) of three hospitals were also tested. The 403 CF isolates were selected at random from a group of strains under evaluation for antibiotic susceptibility and genotyping studies. The non-CF bronchiectatic strains were taken from all patients with non-CF bronchiectasis from whom P. aemginosa was isolated from the sputum during a four-week period in 1989. The non-bronchiectatic clinical and environmental isolates were obtained from 20 hospitals distributed throughout the UK from whom requests for strain identification had been received by the Gram Negative Unit, Division of Hospital Infection, C.P.H.L., London.
Test for auxotrophy
Isolates were grown overnight on King's 'A' agar [9] at 37°C and 5-10 colonies were dispersed in 5 ml of distilled water to give an opacity corresponding to Macfarland 0.5 standard, containing approximately I(1 x cfu/ml. This suspension was diluted 1 : 10(I in distilled water and 0.3 #,1 was spotted onto a minimal salt medium (MSM) [10] and a nutritionally complete medium, King's 'A' agar, with the aid of a multipoint inoculator (Mast Laboratories, Merscysidc, UK); the final inoculum on the agar being approximately l(l a to 10 "~ cfu. MSM contained 75 ml of 2% agar to which, when molten, 6 ml of distilled wvter, 1 ml of 20% glucose (final concentration 0.2%) and 18 ml of a sterile solution of salts were added. Plates were examined after 48 h at 37°C; prototrophic isolates grew on both media and auxotrophs grew on the complete medium only.
htentification of specific growth factors
The experimental design described by Holliday [1 I] was used in which 36 growth factors, including 23 amino acids (t,-forms, Sigma, St. Louis, MO) were evaluated. Individual stock solutions of each factor were prepared aseptically, at the conccntrations indicated by Holliday, by dissolving the constituents in either sterile distilled water or the appropriate organic solvents [12] . All solutions were filter-sterilised, and six factors were combined aseptically in equal volumes to form 12 different pools [11] . The MSM plates were made similarly with 6 ml distilled water replacing 6 × 1 ml growth factors. Isolates were inoculated as above onto: a) all 12 pools, b) King's 'A' agar, c) MSM alone. The control strains of Escherichm coil, M254'"'% J53.2 ~r'/'''~ and J62 p'/m~/f'yp were inoculated similarly. Growth was assessed after 48 h at 37°C. A single growth factor requirement is indicated by growth on two of the 12 i:ools only; growth on one pool alone implies a need for two or more factors in that pool; an alternative requirement is indicated by growth on more than two pools [11].
Confirmation oJ'growth requiremotts
Isolates were inoculated onto: a) minimal medium supplemented with a single growth factor (20 #g/ml), b) King's 'A' agar, and c) minimal medium alone. Table I shows that 74 of 403 (18.4C/~) CF sputum isolates were auxotrophic and were harboured by 49 and 136 {36.0%) patients. Two isolates from I 1 patients with non-CF bronehiectasis were auxotrophic and all q9 isolates from other clinical and environmental sources were prototrophie.
RESULTS
4,1. Auxotrophic screen
Phenotypic api~'arance of a~trotrophs
Both mucoid and non-mucoid strains grew equally well on MSM and King's "A" agar, although pigment (pyocyanin)was not produced on MSM, Auxotrophs expressed both mucoid and non-mucoid phenotypes.
Speci)~c growth factors
Twenty-two of 55 (40.0%) isolates grew on only two pools of growth factors, i.e. required a Alternati,ec and multiple 8 7
Not identified t) 6 single growth factor (Table 2) . Of these, 17 (77.3%) isolated from 13 CF patients were methionine-depcndcnt. Sixteen of 55 (29.1'~) grew on only one pool, i.e. required two or more growth factors and eight (14.6%' } required enultipie factors. The factors necessary for growth were not identified for 9 of the 55 (16,4c~) auxotrophs studied. All control strains grew on the appropriate I~g~ls, and 17 methionine-dependent isolates grew on both the minimal medium supptementcd with methionine (20 p.g/mi) and also the nutritionally complete medium.
DISCUSSION
it is unclear why P. aerteginosa persists in the lungs of patients in vast numbers despite aggressive anti-pseudomonal therapy. The factors which enable the organism to grow and multiply within the pulmonary environment have received little attention in the literalure. The requirement for particular growth factors by some and not all members of a bacterial species suggests that an underlying specific, biosynthetic defect has developed. We report for the first time that auxotrophy of pulmonary, isolates of P. aen~ginosa is a feature of CF and chronic lung sepsis. Growth factors may differ between patients, and methionine is an important single factor required by many strains for growth. It is of interest that the methionine-dependent strains did not grow in a medium supplemented with those amino acids which may be converted to methionine, namely scrine and cysteine. This suggests that the interruption in the bacterial methionine synthetic pathway is located distal to both these amino acids.
Auxotrophic bacteria may be selected in vivo by antibiotic therapy, [13] and indeed, both thymidine auxotrophy in S. aureus in CF [141 and methionine auxotrophy in Neisseria gonorrhoeae have previously been reported [13] . Having described auxotrophy of P. aeniginosa in CF and defined some of the specific growth lequirements in vitro, it may be important to investigate the mechanisms which give rise to these mutants and 24f~ to establish the clinical significance of these findings,
